- Home
- RITR vs FDMT Comparison
RITR vs FDMT Comparison
Compare RITR & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITR
- FDMT
- Stock Information
- Founded
- RITR 2015
- FDMT 2013
- Country
- RITR Hong Kong
- FDMT United States
- Employees
- RITR N/A
- FDMT N/A
- Industry
- RITR
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- RITR
- FDMT Health Care
- Exchange
- RITR NYSE
- FDMT Nasdaq
- Market Cap
- RITR 221.1M
- FDMT 192.2M
- IPO Year
- RITR 2024
- FDMT 2020
- Fundamental
- Price
- RITR $4.54
- FDMT $4.32
- Analyst Decision
- RITR
- FDMT Buy
- Analyst Count
- RITR 0
- FDMT 10
- Target Price
- RITR N/A
- FDMT $32.33
- AVG Volume (30 Days)
- RITR 852.4K
- FDMT 436.5K
- Earning Date
- RITR 02-15-2025
- FDMT 08-07-2025
- Dividend Yield
- RITR N/A
- FDMT N/A
- EPS Growth
- RITR N/A
- FDMT N/A
- EPS
- RITR 0.09
- FDMT N/A
- Revenue
- RITR $47,948,887.00
- FDMT $23,000.00
- Revenue This Year
- RITR N/A
- FDMT $13,048.65
- Revenue Next Year
- RITR N/A
- FDMT N/A
- P/E Ratio
- RITR $52.48
- FDMT N/A
- Revenue Growth
- RITR 278.44
- FDMT N/A
- 52 Week Low
- RITR $2.24
- FDMT $2.24
- 52 Week High
- RITR $8.75
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- RITR N/A
- FDMT 57.43
- Support Level
- RITR N/A
- FDMT $3.86
- Resistance Level
- RITR N/A
- FDMT $4.48
- Average True Range (ATR)
- RITR 0.00
- FDMT 0.28
- MACD
- RITR 0.00
- FDMT 0.01
- Stochastic Oscillator
- RITR 0.00
- FDMT 89.81
About RITR REITAR LOGTECH HLDGS LTD
Reitar Logtech Holdings Ltd provide one-stop solutions for logistics property operations in property development and redevelopment projects. It consists of two segments: construction management and engineering design services; and asset management and professional consultancy services in Hong Kong. Key revenue is generated from construction management and engineering design services.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.